A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-160…

Overview of attention for article published in Journal of Thoracic Oncology, January 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 2 X users
patent: 1 patent

facebook: 1 Facebook page
guideline: 2 clinical guideline sources

Readers on

mendeley: 97 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,104 followers.

@HenryJOncology Atezo is effective w/chemo in SCLC, single agent is not - https://t.co/tiCngeWVsR just like nivo & maintenance pembro. Giving IO earlier w/ chemo likely most effective approach overall. Await 1st line trial results MK604 w/pembro &a…

Brutte news per il microcitoma: https://t.co/0rCsy5UeLg. Uno studio policentrico francese esclude benefici dell'immunoterapia (Atezolizumab: https://t.co/D6z3lhe9TG) nella terapia di seconda linea del carcinoma a piccole cellule (noto anche come microc…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.